Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Clinical trial NCT02228096 · COMPLETED

Trial details

NCT number: NCT02228096
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Relapsed B-cell Acute Lymphoblastic Leukemia Refractory B-cell Acute Lymphoblastic Leukemia

Start date: 2014-08-14
Primary completion: 2018-05-29
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.